MAM-2201

MAM-2201

Legal status
Legal status	CA: Schedule II DE: Anlage II (Prohibited) Temporary Class Drug (NZ)
Identifiers
IUPAC name (1-(5-fluoropentyl)-1H-indol-3-yl)(4-methyl-1-naphthalenyl)-methanone
CAS Number	1354631-24-5
PubChem (CID)	66570720
ChemSpider	28289977
Chemical and physical data
Formula	C25H24FNO
Molar mass	373.462 g/mol
3D model (Jmol)	Interactive image
SMILES FCCCCCn(c4)c2ccccc2c4C(=O)c3ccc(C)c1ccccc13
InChI InChI=1S/C25H24FNO/c1-18-13-14-22(20-10-4-3-9-19(18)20)25(28)23-17-27(16-8-2-7-15-26)24-12-6-5-11-21(23)24/h3-6,9-14,17H,2,7-8,15-16H2,1H3 Key:IGBHZHCGWLHBAE-UHFFFAOYSA-N

MAM-2201 (4'-methyl-AM-2201, 5"-fluoro-JWH-122) is a drug that presumably acts as a potent agonist for the cannabinoid receptors.^[1] It had never previously been reported in the scientific or patent literature, and was first identified by laboratories in the Netherlands and Germany in June 2011 as an ingredient in synthetic cannabis smoking blends.^[2][3][4] Like RCS-4 and AB-001, MAM-2201 thus appears to be a novel compound invented by "research chemical" suppliers specifically for grey-market recreational use. Structurally, MAM-2201 is a hybrid of two known cannabinoid compounds JWH-122 and AM-2201, both of which had previously been used as active ingredients in synthetic cannabis blends before being banned in many countries.

A study of MAM-2201 in rats showed that it causes neurofunctional disruptions.^[5]

Legal Status

MAM-2201 has been banned by being added to the temporary class drug schedule in New Zealand, effective from 13 July 2012.^[6]

As of October 2015 MAM-2201 is a controlled substance in China.^[7]

See also

• EAM-2201
• NM-2201
• THJ-2201
• Structural scheduling of synthetic cannabinoids

References

1. Kei Zaitsu; Hiroshi Nakayama; Mayumi Yamanaka; Kazuaki Hisatsune; Kentaro Taki; Tomomi Asano; Tooru Kamata; Munehiro Katagai; Yumi Hayashi; Maiko Kusano; Hitoshi Tsuchihashi; Akira Ishii (November 2015). "High-resolution mass spectrometric determination of the synthetic cannabinoids MAM-2201, AM-2201, AM-2232, and their metabolites in postmortem plasma and urine by LC/Q-TOFMS". International Journal of Legal Medicine. 129 (6): 1233–1245. doi:10.1007/s00414-015-1257-4. PMID 26349566.
2. EMCDDA–Europol 2011 Annual Report on the implementation of Council Decision 2005/387/JHA
3. Moosmann, B.; et al. (2012). "Separation and structural characterization of the synthetic cannabinoids JWH-412 and 1-(5-fluoropentyl)-1H-indol-3yl]-(4-methylnaphthalen-1-yl)methanone using GC–MS, NMR analysis and a flash chromatography system". Forensic Science International. 220 (1–3): e17–e22. doi:10.1016/j.forsciint.2011.12.010. PMID 22264627.
4. Simolka, K.; et al. (2012). "Analysis of synthetic cannabinoids in "spice-like" herbal highs: Snapshot of the German market in summer 2011". Analytical and Bioanalytical Chemistry. 404 (1): 157–171. doi:10.1007/s00216-012-6122-4. PMID 22710567.
5. Zaitsu, K; Hayashi, Y; Suzuki, K; Nakayama, H; Hattori, N; Takahara, R; Kusano, M; Tsuchihashi, H; Ishi, A (2015). "Metabolome disruption of the rat cerebrum induced by the acute toxic effects of the synthetic cannabinoid MAM-2201". Life Sciences. 137: 49–55. doi:10.1016/j.lfs.2015.05.013. PMID 26032255.
6. Temporary Class Drug Notice, 5 July 2012. NZ Department of Internal Affairs.
7. "关于印发《非药用类麻醉药品和精神药品列管办法》的通知" (in Chinese). China Food and Drug Administration. 27 September 2015. Retrieved 1 October 2015.